Increases bone mineral density & reduces incidence of hip, vertebral & non-vertebral fractures in postmenopausal women w/ osteoporosis at increased risk of fracture. Bone loss in patients undergoing hormone ablation for prostate or aromatase inhibitor treatment for breast cancer. Reduces incidence of vertebral fractures in patients w/ prostate cancer. Increases bone mass in men w/ osteoporosis at increased risk of fracture. Glucocorticoid-induced osteoporosis in men & women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in daily dosage equiv to prednisone ≥7.5 mg & expected to remain on glucocorticoid for at least 6 mth.